Photodynamic therapy (PDT) is a cancer treatment that uses a drug, called a photosensitizer or photosensitizing agent, and a particular type of light.
PDT Cancer Center in Indonesia
Establishment of SPC, PT Great Mataram
​
-
PT Buckingham Investment Holdings (“PT Buckingham”) is a subsidiary of Buckingham Investment Limited in Indonesia.
-
PT Buckingham established a SPC to carry out PDT project. The SPC is PT Great Mataram. It is a Joint-Venture SPC established in Jakarta, Indonesia.
-
It is a JV established jointly by PT Buckingham Holdings Indonesia and PT Mepro.
-
PT Mepro is a pharmaceutical company of Indonesia.
-
PT Great Mataram has a pharmaceutical distribution permit. The role of the company is to import pharmaceutical products and to carry on PDT projects.
-
We will import and distribute photosensitizer.
Introduction of Photodynamic therapy
​
-
Photodynamic therapy (PDT) is a form of phototherapy involving light and a photosensitizing chemical substance, used in conjunction with molecular oxygen to elicit cell death.
-
PDT has proven ability to kill microbial cells, including bacteria, fungi and viruses.
-
It is recognized as a treatment strategy that is both minimally invasive and minimally toxic.
-
Photodynamic therapy's advantages lessen the need for delicate surgery and lengthy recuperation and minimal formation of scar tissue and disfigurement.
​
Advantages for PDT:
​
-
It has no long-term side effects when used properly.
-
It’s less invasive than surgery.
-
It usually takes only a short time and is most often done as an outpatient.
-
It can be targeted very precisely.
-
Unlike radiation, PDT can be repeated many times at the same site if needed.
-
There’s usually little or no scarring after the site heals.
-
It costs less than other cancer treatments.
PDT Structure
​
-
Photodynamic therapy (PDT) relies on the combination of a photosensitive drug, known as a photosensitizer, with light of the proper wavelength and molecular oxygen to generate cytotoxic reactive oxygen species.
-
The synergy of drugs and devices represents an enormous and largely untapped potential for both clinical progress and corporate profit.
​​